Literature DB >> 11353796

Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating.

V Rybalchenko1, N Prevarskaya, F Van Coppenolle, G Legrand, L Lemonnier, X Le Bourhis, R Skryma.   

Abstract

The mechanisms of verapamil and tetraethylammonium (TEA) inhibition of voltage-gated K+ channels in LNCaP human prostate cancer cells were studied in whole-cell and outside/inside-out patch-clamp configurations. Rapidly activating outward K+ currents (I(K)) exhibited neither C-type, nor rapid (human ether á go-go-related gene-type) inactivation. With 2 mM [Mg(2+)](o), I(K) activation kinetics was independent of holding potential, suggesting the absence of ether á go-go-type K+ channels. Extracellular applications of TEA and verapamil (IC(50) = 11 microM) rapidly (12 s) inhibited I(K) in LNCaP cells. Blocking was also rapidly reversible. Intracellular TEA (1 mM), verapamil (1 mM), and membrane-impermeable N-methyl-verapamil (25 microM) did not influence whole-cell I(K), although both phenylalkylamines inhibited single-channel currents in inside-out patches. Extracellular application of N-methyl-verapamil (25 microM) had no influence on I(K). Our results are compatible with the hypothesis that, in LNCaP cells expressing C-type inactivation-deficient voltage-activated K+ channels, phenylalkylamines interact with an intracellular binding site, and probably an additional hydrophobic binding site that does not bind charged phenylalkylamines. The inhibiting effects of verapamil and TEA on I(K) were additive, suggesting independent K+-channel blocking mechanisms. Indeed, TEA (1 mM) reduced a single-channel conductance (from 7.3 +/- 0.5 to 3.2 +/- 0.4 pA at a membrane potential of +50 mV, n = 6), whereas verapamil (10 microM) reduced an open-channel probability (from 0.45 +/- 0.1 in control to 0.1 +/- 0.09 in verapamil-treated cells, n = 9). The inhibiting effects of verapamil and TEA on LNCaP cell proliferation were not multiplicative, suggesting that both share a common antiproliferative mechanism initiated through a K+ channel block.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353796     DOI: 10.1124/mol.59.6.1376

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  Inhibition of the activity of human lymphocyte Kv1.3 potassium channels by resveratrol.

Authors:  Andrzej Teisseyre; Krystyna Michalak
Journal:  J Membr Biol       Date:  2007-06-05       Impact factor: 1.843

2.  The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination.

Authors:  Masaharu Kogure; Masashi Takawa; Vassiliki Saloura; Kenbun Sone; Lianhua Piao; Koji Ueda; Reem Ibrahim; Tatsuhiko Tsunoda; Masanori Sugiyama; Yutaka Atomi; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

3.  Genistein inhibits the activity of kv1.3 potassium channels in human T lymphocytes.

Authors:  A Teisseyre; K Michalak
Journal:  J Membr Biol       Date:  2005-05       Impact factor: 1.843

4.  Modulatory Effect of Selected Dietary Phytochemicals on Delayed Rectifier K+ Current in Human Prostate Cancer Cells.

Authors:  Kiran George; Nisha Susan Thomas; Raman Malathi
Journal:  J Membr Biol       Date:  2019-06-04       Impact factor: 1.843

5.  Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.

Authors:  Aybike Birerdinc; Elizabeth Nohelty; Andrey Marakhonov; Ganiraju Manyam; Ivan Panov; Stephanie Coon; Eugene Nikitin; Mikhail Skoblov; Vikas Chandhoke; Ancha Baranova
Journal:  Tumour Biol       Date:  2009-12-18

6.  Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation.

Authors:  Fabien Van Coppenolle; Roman Skryma; Halima Ouadid-Ahidouch; Christian Slomianny; Morad Roudbaraki; Philippe Delcourt; Etienne Dewailly; Sandrine Humez; Alexandre Crépin; Isabelle Gourdou; Jean Djiane; Jean-Louis Bonnal; Brigitte Mauroy; Natalia Prevarskaya
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

7.  Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.

Authors:  Saroj Niraula; Greg Pond; Ronald de Wit; Mario Eisenberger; Ian F Tannock; Anthony M Joshua
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

8.  Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells.

Authors:  Stephanie Thebault; Morad Roudbaraki; Vadim Sydorenko; Yaroslav Shuba; Loic Lemonnier; Christian Slomianny; Etienne Dewailly; Jean-Louis Bonnal; Brigitte Mauroy; Roman Skryma; Natalia Prevarskaya
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

9.  The association between calcium channel blocker use and prostate cancer outcome.

Authors:  Michael A Poch; Diana Mehedint; Dawn J Green; Rochelle Payne-Ondracek; Elizabeth T H Fontham; Jeannette T Bensen; Kristopher Attwood; Gregory E Wilding; Khurshid A Guru; Willie Underwood; James L Mohler; Hannelore V Heemers
Journal:  Prostate       Date:  2012-12-31       Impact factor: 4.104

10.  Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breast cancer cell line.

Authors:  Sébastien Roger; Jean-Yves Le Guennec; Pierre Besson
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.